Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

iPS Cell Differentiation

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Altered Busulphan Exposure Associated with Concomitant Omeprazole during Hematopoietic Stem Cell Transplantation Conditioning: A Two-Case Report.

Clinical drug investigation·2026

Same author

Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.

JCO oncology practice·2026

Same author

International Survey and Next-Generation Sequencing-Based Indel Chimerism Detection of Human Leukocyte Antigens Loss in Relapsed Haploidentical and Mismatched Unrelated Donor Transplant Recipients.

Transplantation and cellular therapy·2026

Same author

Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026

Same author

Toward a Standardized Definition of Reduced-Dose Post-transplant Cyclophosphamide in Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Same author

Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Recent progress in allogeneic stem cell transplantation.

Jonas Mattsson¹

¹Karolinska Institutet, Karolinska University Hospital, Center for Allogeneic Stem Cell Transplantation, Huddinge, SE-141 86 Stockholm, Sweden. Jonas.Mattsson@ki.se

Current Opinion in Molecular Therapeutics

|August 7, 2008

Summary

Allogeneic hematopoietic stem cell transplantation (ASCT) offers improved survival for immunohematopoietic diseases. Advances include better HLA matching, reduced-intensity conditioning, and home care, alongside strategies to enhance graft-versus-tumor effects.

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Related Experiment Videos

Last Updated: Jul 3, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Area of Science:

Hematology
Immunology
Oncology

Background:

Allogeneic hematopoietic stem cell transplantation (ASCT) is a standard treatment for hematologic malignancies and non-malignant immune disorders.
Increasing use of matched unrelated donors and improved HLA matching have enhanced survival rates.
Peripheral blood and cord blood stem cells are increasingly utilized.

Purpose of the Study:

To review recent advancements in clinical allogeneic hematopoietic stem cell transplantation.
To highlight new strategies for improving ASCT outcomes and patient management.
To discuss novel approaches for managing graft-versus-host disease and enhancing graft-versus-tumor effects.

Main Methods:

Review of current literature on allogeneic hematopoietic stem cell transplantation.
Analysis of novel conditioning regimens, including reduced-intensity conditioning.
Exploration of immunomodulatory strategies and donor selection criteria.

Main Results:

Improved survival with advanced HLA matching and use of unrelated donors.
Reduced-intensity conditioning offers an alternative for specific patient populations.
Potential biomarkers (caspase recruitment domain containing protein 15 mutations, regulatory T-cells) for graft-versus-host disease risk identified.
Mesenchymal stem cells show promise for steroid-refractory graft-versus-host disease.
Graft-versus-tumor and graft-versus-leukemia effects can be enhanced through various strategies, including minor histocompatibility antigen differences and natural killer cell alloreactivity.
ASCT demonstrates graft-versus-tumor effects in solid tumors.

Conclusions:

Clinical ASCT has seen significant progress, improving patient survival and expanding treatment options.
New approaches are emerging for managing GVHD and optimizing GVT/GVL effects.
Future directions include further refinement of donor selection, conditioning regimens, and immunomodulatory therapies.